Scarica l'app Stockscreener
26.78
0.02%
-0.0091
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$26.79
Aprire:
$26.81
Volume 24 ore:
1.33M
Relative Volume:
0.44
Capitalizzazione di mercato:
$1.43B
Reddito:
$75.04M
Utile/perdita netta:
$-167.18M
Rapporto P/E:
-8.3777
EPS:
-3.1967
Flusso di cassa netto:
$-168.39M
1 W Prestazione:
+0.06%
1M Prestazione:
+36.45%
6M Prestazione:
+89.96%
1 anno Prestazione:
+133.52%
Intervallo 1D:
$26.77
$26.82
Intervallo di 1 settimana:
$26.76
$26.83
Portata 52W:
$9.83
$26.85
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Nome
Kalvista Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 999-0075
Indirizzo
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
26.78 | 1.43B | 75.04M | -167.18M | -168.39M | -3.1967 |
VRTX
Vertex Pharmaceuticals Inc
|
437.08 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.41 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.97 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.02 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.59 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Reiterato | Needham | Buy |
| 2026-01-06 | Reiterato | Needham | Buy |
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-12-18 | Iniziato | BofA Securities | Buy |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-29 | Iniziato | SVB Leerink | Outperform |
| 2019-03-20 | Iniziato | Needham | Buy |
| 2018-10-30 | Iniziato | Jefferies | Buy |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Iniziato | BTIG Research | Buy |
Mostra tutto
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
Why (KALV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Frazier Life Sciences funds (NASDAQ: KALV) disclose updated KalVista ownership - Stock Titan
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? - TradingView
KalVista (KALV) CEO nets RSU shares after tax-related stock sale - Stock Titan
KalVista (KALV) CDO sells shares to cover RSU tax obligations - Stock Titan
KalVista Pharmaceuticals (KALV) CMO covers RSU taxes with 1,032-share sale - Stock Titan
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc.KALV - Business Wire
KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47 - MSN
The $1.9 Billion Bet: Chiesi Acquires KalVista, Redefining Rare Disease Value - Kavout
Assessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum - simplywall.st
Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks - TipRanks
Point72 entities report 4.2% stake in KalVista (NASDAQ: KALV) — 2.14M shares - Stock Titan
Brodsky & Smith investigates fiduciary duty breaches in mergers of KalVista, Thermon, Sila, and Lisata. - Pluang
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN
Chiesi to acquire KalVista (NASDAQ: KALV) in $27 per share cash deal - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA) - GlobeNewswire Inc.
KalVista to offer $110M in convertible notes; shares down 10% - MSN
Understanding Momentum Shifts in (KALV) - Stock Traders Daily
KalVista CEO Benjamin Palleiko sells $88,730 in company stock By Investing.com - Investing.com India
Kalvista Pharmaceuticals stock hits 52-week high at $26.85 By Investing.com - Investing.com Nigeria
KalVista CEO Benjamin Palleiko sells $88,730 in company stock - Investing.com
KalVista (NASDAQ: KALV) board backs $27 cash tender offer and planned merger - Stock Titan
SilverArc (KALV) files 2.88M-share Schedule 13G stake disclosure - Stock Titan
KalVista (KALV) CEO Palleiko sells shares to cover taxes after RSU vesting - Stock Titan
Kalvista Pharmaceuticals stock hits 52-week high at $26.85 - Investing.com
Chiesi (NASDAQ: KALV) offers $27.00 per share to acquire KalVista - Stock Titan
TradingKey - TradingKey
Citizens Maintains KalVista Pharmaceuticals (KALV) Market Outperform Recommendation - MSN
F m Investments LLC Purchases 37,486 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - AOL.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Hold Rating, Maintains Target Price $27 - Moomoo
Chiesi Continues Hunt For Rare Disease Drugs After KalVista Acquisition - Citeline News & Insights
Press Release Distribution India - Business Wire India
Stifel Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
Chiesi to buy Kalvista, developer of HAE treatment Ekterly - Angioedema News
Kalvista Pharmaceuticals stock hits 52-week high at 26.77 USD By Investing.com - Investing.com Australia
Kalvista Pharmaceuticals stock hits 52-week high at 26.77 USD - Investing.com
Needham downgrades KalVista Pharmaceuticals (KALV) - MSN
Chiesi Farmaceutici (NASDAQ: KALV) offers $27.00 per share to buy KalVista - Stock Titan
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal - MSN
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? - Sahm
Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kalvista Pharmaceuticals Inc Azioni (KALV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
May 18 '26 |
Sale |
26.76 |
1,032 |
27,616 |
143,934 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
May 18 '26 |
Sale |
26.76 |
1,129 |
30,212 |
467,665 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
May 12 '26 |
Sale |
26.71 |
3,322 |
88,731 |
466,375 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Apr 17 '26 |
Sale |
20.22 |
2,686 |
54,301 |
142,547 |
| Sweeny Nicole | Chief Commercial Officer |
Apr 17 '26 |
Sale |
20.22 |
1,862 |
37,643 |
51,391 |
| Piekos Brian | Chief Financial Officer |
Apr 17 '26 |
Sale |
20.22 |
1,862 |
37,643 |
18,150 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Apr 17 '26 |
Sale |
20.22 |
9,550 |
193,066 |
462,577 |
| Venrock Healthcare Capital Par | 10% Owner |
Mar 25 '26 |
Sale |
16.95 |
174,645 |
2,960,326 |
5,129,340 |
| Venrock Healthcare Capital Par | 10% Owner |
Mar 26 '26 |
Sale |
18.28 |
39,986 |
730,822 |
5,089,354 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Mar 09 '26 |
Sale |
16.08 |
6,693 |
107,633 |
451,815 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):